Protalix BioTherapeutics (PLX) Amortization of Deferred Charges (2013 - 2023)

Protalix BioTherapeutics' Amortization of Deferred Charges history runs 11 years deep, the most recent figure standing at $59000.0 for Q4 2023.

• On a quarterly basis, Amortization of Deferred Charges fell 22.37% year-over-year to $59000.0 in Q4 2023; TTM through Dec 2023 was $267000.0, a 11.0% decrease from a year earlier, with the FY2023 full-year figure at $267000.0, down 11.0% from the prior year.
• Amortization of Deferred Charges retreated to $59000.0 in Q4 2023 per PLX's latest filing, from $60000.0 in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $983000.0 in Q2 2021 and bottomed at $59000.0 in Q4 2023.
• The 5-year median for Amortization of Deferred Charges is $672500.0 (2019), against an average of $485050.0.
• Across the five-year window, Amortization of Deferred Charges gained 16.48% in 2020 and slumped 92.78% in 2022, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $794000.0 in 2019, then climbed by 16.12% to $922000.0 in 2020, then sank by 88.72% to $104000.0 in 2021, then declined by 26.92% to $76000.0 in 2022, then decreased by 22.37% to $59000.0 in 2023.
• Per Business Quant, the three latest PLX Amortization of Deferred Charges figures stand at $59000.0 (Q4 2023), $60000.0 (Q3 2023), and $68000.0 (Q2 2023).